IL17A and inflammatory bowel disease: It’s noteworthy that to date, there are no ongoing clinical trials specifically targeting the IL-17 pathway for inflammatory bowel disease, signifying the need for further research to understand its role and develop safer, more effective treatments tailored to these diseases.